A patient‑level meta‑analysis of randomized trials finds transcatheter aortic valve implantation (TAVI) reduces 1‑year risk of death or stroke versus surgical AVR in low– to intermediate‑risk patients—informing patient selection, heart‑team decisions, and follow‑up priorities.